Total Payments
$25,484
2024 Payments
$7,601
Companies
13
Transactions
40
Medicare Patients
579
Medicare Billing
$155,186
Payment Breakdown by Category
Consulting$18,814 (73.8%)
Other$3,300 (12.9%)
Travel$1,892 (7.4%)
Food & Beverage$770.61 (3.0%)
Research$700.00 (2.7%)
Education$7.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $18,814 | 9 | 73.8% |
| Honoraria | $3,300 | 1 | 12.9% |
| Travel and Lodging | $1,892 | 11 | 7.4% |
| Food and Beverage | $770.61 | 17 | 3.0% |
| Unspecified | $700.00 | 1 | 2.7% |
| Education | $7.00 | 1 | 0.0% |
Payments by Type
General
$24,784
39 transactions
Research
$700.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $6,067 | 11 | $0 (2020) |
| National Marrow Donor Program | $5,311 | 3 | $0 (2024) |
| Agios Pharmaceuticals, Inc. | $4,109 | 10 | $0 (2018) |
| PFIZER INC. | $2,716 | 3 | $0 (2017) |
| Gamida Cell Inc. | $2,550 | 1 | $0 (2024) |
| Terumo BCT, Inc. | $2,250 | 3 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $1,200 | 1 | $0 (2023) |
| Octapharma USA, Inc. | $700.00 | 1 | $0 (2021) |
| TerSera Therapeutics LLC | $362.00 | 1 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $118.37 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,601 | 5 | National Marrow Donor Program ($5,000) |
| 2023 | $1,200 | 1 | Janssen Scientific Affairs, LLC ($1,200) |
| 2022 | $673.44 | 3 | TerSera Therapeutics LLC ($362.00) |
| 2021 | $700.00 | 1 | Octapharma USA, Inc. ($700.00) |
| 2020 | $124.87 | 1 | Incyte Corporation ($124.87) |
| 2019 | $936.71 | 2 | Terumo BCT, Inc. ($900.00) |
| 2018 | $5,277 | 12 | Agios Pharmaceuticals, Inc. ($4,109) |
| 2017 | $8,970 | 15 | Incyte Corporation ($5,943) |
All Payment Transactions
40 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/19/2024 | Gamida Cell Inc. | OMISIRGE (Biological) | Consulting Fee | Cash or cash equivalent | $2,550.00 | General |
| Category: ONCOLOGY | ||||||
| 08/15/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: ONCOLOGY | ||||||
| 05/31/2024 | National Marrow Donor Program | — | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| 05/08/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $22.03 | General |
| Category: ONCOLOGY | ||||||
| 04/04/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $13.46 | General |
| Category: ONCOLOGY | ||||||
| 06/20/2023 | Janssen Scientific Affairs, LLC | CARVYKTI (Drug) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: Oncology | ||||||
| 09/07/2022 | National Marrow Donor Program | — | Travel and Lodging | In-kind items and services | $155.72 | General |
| 09/07/2022 | National Marrow Donor Program | — | Travel and Lodging | In-kind items and services | $155.72 | General |
| 03/11/2022 | TerSera Therapeutics LLC | — | Consulting Fee | Cash or cash equivalent | $362.00 | General |
| 03/25/2021 | Octapharma USA, Inc. | PANZYGA (Biological) | — | Cash or cash equivalent | $700.00 | Research |
| Study: NGAM-12 • Category: IMMUNOLOGY | ||||||
| 10/13/2020 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $124.87 | General |
| Category: Oncology | ||||||
| 12/12/2019 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $36.71 | General |
| 10/08/2019 | Terumo BCT, Inc. | Mirasol Pathogen Reduction Technology System (Device) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Pathogen reduction | ||||||
| 10/15/2018 | Agios Pharmaceuticals, Inc. | — | Honoraria | Cash or cash equivalent | $3,300.00 | General |
| 10/04/2018 | Terumo BCT, Inc. | Mirasol Pathogen Reduction Technology System (Device) | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| Category: Pathogen reduction | ||||||
| 09/28/2018 | Agios Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $55.00 | General |
| 09/28/2018 | Agios Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $41.44 | General |
| 09/28/2018 | Agios Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $40.00 | General |
| 09/28/2018 | Agios Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 09/28/2018 | Agios Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $13.85 | General |
| 09/28/2018 | Agios Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $13.85 | General |
| 09/27/2018 | Agios Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $349.90 | General |
| 09/27/2018 | Agios Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $145.22 | General |
| 09/27/2018 | Agios Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $119.75 | General |
| 05/24/2018 | Merck Sharp & Dohme Corporation | PREVYMIS (Drug) | Food and Beverage | In-kind items and services | $118.37 | General |
| Category: INFECTIOUS DISEASE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NGAM-12 | Octapharma USA, Inc. | $700.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 116 | 465 | $188,964 | $42,724 |
| 2022 | 4 | 146 | 430 | $175,268 | $35,166 |
| 2021 | 4 | 141 | 418 | $164,108 | $34,783 |
| 2020 | 4 | 176 | 545 | $209,336 | $42,513 |
Total Patients
579
Total Services
1,858
Medicare Billing
$155,186
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 52 | 347 | $142,964 | $33,378 | 23.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 32 | 86 | $33,368 | $6,779 | 20.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 21 | 21 | $6,340 | $1,377 | 21.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 11 | 11 | $6,292 | $1,191 | 18.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 64 | 280 | $115,360 | $23,174 | 20.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 41 | 107 | $41,516 | $8,472 | 20.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 20 | 21 | $12,012 | $2,284 | 19.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 21 | 22 | $6,380 | $1,236 | 19.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 53 | 246 | $101,352 | $20,632 | 20.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 49 | 132 | $45,972 | $10,454 | 22.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 24 | 24 | $12,144 | $2,757 | 22.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 15 | 16 | $4,640 | $939.84 | 20.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 76 | 370 | $152,440 | $31,422 | 20.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 58 | 132 | $41,137 | $8,013 | 19.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 21 | 22 | $9,669 | $1,825 | 18.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 21 | 21 | $6,090 | $1,253 | 20.6% |
About Dr. Jonathan Gutman, MD
Dr. Jonathan Gutman, MD is a Hematology & Oncology healthcare provider based in Aurora, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1003882952.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Gutman, MD has received a total of $25,484 in payments from pharmaceutical and medical device companies, with $7,601 received in 2024. These payments were reported across 40 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($18,814).
As a Medicare-enrolled provider, Gutman has provided services to 579 Medicare beneficiaries, totaling 1,858 services with total Medicare billing of $155,186. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Aurora, CO
- Active Since 02/28/2006
- Last Updated 11/19/2018
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1003882952
Products in Payments
- JAKAFI (Drug) $5,943
- OMISIRGE (Biological) $2,550
- Mirasol Pathogen Reduction Technology System (Device) $1,950
- CARVYKTI (Drug) $1,200
- PANZYGA (Biological) $700.00
- Mirasol (Device) $300.00
- MYLOTARG (Drug) $176.88
- MONJUVI (Drug) $124.87
- PREVYMIS (Drug) $118.37
- VENCLEXTA (Drug) $51.36
- Pomalyst (Drug) $11.60
- BOSULIF (Drug) $7.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Aurora
Douglas Reznick, Md, MD
Hematology & Oncology — Payments: $559,713
Hematology & Oncology $559,713
John Burke, Md, MD
Hematology & Oncology — Payments: $396,476
Hematology & Oncology $396,476
Dr. Daniel Pollyea, Md, MD
Hematology & Oncology — Payments: $385,448
Hematology & Oncology $385,448
Tomer Mark, Md, Msc, MD, MSC
Hematology & Oncology — Payments: $260,683
Hematology & Oncology $260,683
Dr. Manali Kamdar, Md, MD
Hematology & Oncology — Payments: $115,652
Hematology & Oncology $115,652
Ara Metjian, Md, MD
Hematology & Oncology — Payments: $85,085
Hematology & Oncology $85,085